Welcome to our dedicated page for Vistagen Therapeutics SEC filings (Ticker: VTGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vistagen Therapeutics, Inc. (Nasdaq: VTGN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Vistagen is a Nevada-incorporated, late clinical-stage biopharmaceutical company headquartered in South San Francisco, California, and its filings offer detailed insight into its nose-to-brain neurocircuitry platform, pherine pipeline, governance, and financial condition.
Through documents such as Form 10-K annual reports and Form 10-Q quarterly reports, readers can review Vistagen’s descriptions of its business as a neuroscience-focused biopharmaceutical company, its intranasal pherine product candidates, and the risks and uncertainties associated with late-stage clinical development. These filings also discuss the company’s focus on indications including social anxiety disorder, major depressive disorder, and vasomotor symptoms (hot flashes) due to menopause, as well as other women’s health conditions.
Current reports on Form 8-K provide timely information on material events, including clinical and corporate milestones. Recent 8-K filings have addressed topics such as financial results for specific fiscal quarters, progress in the PALISADE Phase 3 program for fasedienol in social anxiety disorder, and changes in executive leadership and board composition. Proxy materials on Form DEF 14A describe matters submitted to a shareholder vote, including director elections, advisory votes on executive compensation, and auditor ratification, along with details about governance practices.
Stock Titan’s platform enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand complex sections on clinical programs, compensation, and shareholder matters. Real-time updates from EDGAR ensure that new Vistagen filings, including any future Forms 4 reporting insider equity awards or transactions, appear promptly, while AI-generated overviews can assist in interpreting how each filing relates to the company’s pherine development strategy and late-stage clinical status.
Vistagen Therapeutics, Inc. (VTGN) filed a Form 4 on 25-Jun-2025 detailing an equity award to its newly appointed Chief Corporate Development Officer, Elissa S. Cote. On 23-Jun-2025 Ms. Cote received 150,000 stock options with an exercise price of $1.96 per share and an expiration date of 23-Jun-2035. The transaction is coded “A,” indicating an acquisition at no cost to the insider.
The options vest 25 % on 23-Jun-2026, with the remaining 75 % vesting in equal monthly installments over the subsequent 36 months, resulting in full vesting three years after the initial cliff. Following the grant, Ms. Cote beneficially owns 150,000 derivative securities and reported no ownership of, or transactions in, non-derivative common shares.
This award forms part of her employment package and aligns her long-term incentives with shareholder interests. Although the grant introduces potential dilution of roughly 150,000 shares, it does not involve any insider selling and therefore has minimal immediate market impact.
Vistagen Therapeutics (VTGN) has filed a Form 3 (Initial Statement of Beneficial Ownership) for Elissa S. Cote, who has been appointed as the company's Chief Corporate Development Officer. The filing date is June 28, 2025, with the triggering event occurring on June 23, 2025.
Key details from the filing:
- The reporting person currently owns no securities of the company, either direct or indirect
- No derivative securities (options, warrants, etc.) are reported as beneficially owned
- This is an individual filing, not a joint/group submission
- The filing address is listed as 343 Allerton Avenue, South San Francisco, CA 94080
This Form 3 filing is a standard regulatory requirement for new officers, directors, and 10% shareholders to disclose their initial ownership positions in the company's securities.
Vistagen Therapeutics (VTGN) Chief Financial Officer Cynthia Lynn Anderson received a new stock option grant on June 23, 2025. The key details of this insider transaction include:
- Granted 100,000 stock options to purchase common stock
- Exercise price set at $1.96 per share
- Options expire on June 23, 2035 (10-year term)
- Vesting schedule: Equal monthly installments over 3 years from grant date
This equity compensation grant was made under the company's Amended and Restated 2019 Equity Omnibus Incentive Plan. The transaction represents a standard long-term incentive award for the CFO, aligning executive interests with shareholders through a three-year vesting period. No immediate shares were acquired or disposed of in this grant.
Form 4 overview: On 06/23/2025 Vistagen Therapeutics, Inc. (VTGN) granted Chief Operating Officer Joshua S. Prince non-qualified stock options to purchase 100,000 shares of common stock at an exercise price of $1.96 per share.
The options were issued under the company’s Amended and Restated 2019 Equity Omnibus Incentive Plan. According to the filing they vest in equal monthly instalments over three years, beginning on the grant date, and expire on 06/23/2035. No cash consideration was paid for the award (price of derivative security reported as $0). After this transaction the reporting person beneficially owns 100,000 derivative securities; no change in Prince’s direct common-stock holdings was disclosed, and no indirect ownership was reported.
The filing is routine and discloses only an incentive option grant; there are no sales, open-market purchases, or other equity transactions. The transaction was coded “A” (acquisition) and filed by a single reporting person. No 10b5-1 trading plan was indicated.
Investor takeaways: (1) The award modestly increases potential insider ownership if the options are exercised, aligning executive incentives with shareholder value creation. (2) The three-year, monthly vesting schedule encourages retention. (3) The strike price of $1.96 establishes the threshold above which the COO could profit over the next decade. No immediate dilution occurs until options are exercised, and the grant size is immaterial relative to Vistagen’s total shares outstanding as of the latest public data (not provided in this filing).